2026 Q3 - tulosraportti
UUTTA
Tänään
‧54 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 640 | ||
| 500 | ||
| 786 | ||
| 2 370 | ||
| 120 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 11.11. | ||
2026 Q2 - tulosraportti 22.7. | ||
2026 Q1 - tulosraportti 23.4. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 30.10.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 t sitten · MuokattuHansa upward trend since April - and on the way out of all resistance. 50 this week is not completely out of the question to imagine. Thinking we will probably check the top from 2/9 with close at 46.68 and intraday 48.22 Thu-Fri - or at the latest next week.
·10 t sittenCosts up by 34,3% - ouch Now burning 213 million per quarter. Zero revenue from products - as expected. License revenue - as expected. Zero new information regarding FDA and SEC (IPO)?? - are you paying attention at all? There won't be anything until December - that is indeed THE binary event we have been waiting for for a long time. So of course the report is completely and utterly as expected.- ·1 päivä sitten"A bearish engulfing candle is a two-bar technical reversal pattern suggesting that an uptrend may be about to turn downward." https://dailypriceaction.com/blog/how-to-trade-the-bearish-engulfing-pattern/+13.3% :-) - not quite downwards in my chart !! One can almost assume with 100% certainty that when you "warn" that NOW NOW NOW your "analyses" have shown that it is in danger of falling - then it rises :-). Your investments must cost you monstrous sums - so I think you are very very rich, if you can afford to follow your own "analyses".
- ·1 päivä sittenWhat can happen tomorrow in connection with the report?I think it is entirely reasonable to monitor the quarterly report as a potential information point for both the FDA process and the U.S. listing. What might happen tomorrow in connection with the report? -Hansa will likely communicate that the FDA process is proceeding according to plan. -The company may provide an update on the SEC process. -We might receive information that a U.S. listing is being prepared ahead of the commercial launch. An approximate timeline for the listing is provided. According to previous information, they could potentially come with two simultaneous offerings: ADS offering: American Depositary Shares representing ordinary shares. Parallel private placement: New ordinary shares sold to qualified investors in Europe. Shareholders who have sold recently might expect dilution from the aforementioned offerings. A listing in the U.S. before a potential approval could make it possible for Hansa to: Establish relationships with U.S. institutional investors. Increase visibility in the U.S. biotech market. Strengthen its financial position ahead of commercialization. Create interest among investors ahead of the FDA decision. If they proceed with the aforementioned offerings before PDUFA - it can also serve as an extra financial safety net if the FDA issues a CRL instead of an approval. This could give Hansa access to new capital before the binary regulatory event. An important detail is that the SEC normally requires the registration statement to be made public at least 15 days prior to a road show when the confidential review process is used. My interpretation is therefore that a capital raise before PDUFA could be rational even if management is optimistic about an approval. It can reduce the risk that the company is forced to raise money under pressure after a negative outcome. At the same time, a large new share issue before the decision could mean significant dilution for existing shareholders. My opinion and no advice. From Hansa 21 Aug 2026: "a potential initial public offering of American Depositary Shares ("ADSs"), representing the Company's ordinary shares, in the United States and a potential concurrent private placement of its ordinary shares in Europe to certain qualified investors (together, the "Global Offering")." From SEC - Enhanced Accommodations for Issuers Submitting Draft Registration Statements Consistent with our past practices, we will continue to review draft initial registration statements submitted under the Securities Act and Exchange Act Section 12(b), and their related revisions, on a nonpublic basis provided that the issuer confirms in a cover letter to the nonpublic draft submission that it will publicly file its registration statement and nonpublic draft submissions at least 15 days prior to any road show or, in the absence of a road show, at least 15 days prior to the requested effective date of the registration statement.
- ·1 päivä sittenOBV:s tekniska läge Kortsiktig struktur: Positiv Långsiktig trend: Fortfarande negativ Viktigaste motstånd:-6,82 M Viktigaste stöd: Stigande blå trendlinje De stigande bottnarna är positiva, men jag skulle vilja se ett utbrott genom motståndet innan jag betraktar OBV som tydligt bullish. OBV ser idag ut att avvisas vid det viktigaste motståndet och kan komma falla ner mot den stigande blå stödlinjen, kommer den under så försvagas den positiva bilden betydligt. Då riskerar vi att få en ny period av distribution. Min åsikt och inget råd.
These analyses are not that interesting in this company, it's probably more FDA yes or no that one sits for
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 231 290 | 2 231 290 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 231 290 | 2 231 290 | 0 | 0 |
2026 Q3 - tulosraportti
UUTTA
Tänään
‧54 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sitten · MuokattuHansa upward trend since April - and on the way out of all resistance. 50 this week is not completely out of the question to imagine. Thinking we will probably check the top from 2/9 with close at 46.68 and intraday 48.22 Thu-Fri - or at the latest next week.
- ·10 t sittenCosts up by 34,3% - ouch Now burning 213 million per quarter. Zero revenue from products - as expected. License revenue - as expected. Zero new information regarding FDA and SEC (IPO)?? - are you paying attention at all? There won't be anything until December - that is indeed THE binary event we have been waiting for for a long time. So of course the report is completely and utterly as expected.
- ·1 päivä sitten"A bearish engulfing candle is a two-bar technical reversal pattern suggesting that an uptrend may be about to turn downward." https://dailypriceaction.com/blog/how-to-trade-the-bearish-engulfing-pattern/+13.3% :-) - not quite downwards in my chart !! One can almost assume with 100% certainty that when you "warn" that NOW NOW NOW your "analyses" have shown that it is in danger of falling - then it rises :-). Your investments must cost you monstrous sums - so I think you are very very rich, if you can afford to follow your own "analyses".
- ·1 päivä sittenWhat can happen tomorrow in connection with the report?I think it is entirely reasonable to monitor the quarterly report as a potential information point for both the FDA process and the U.S. listing. What might happen tomorrow in connection with the report? -Hansa will likely communicate that the FDA process is proceeding according to plan. -The company may provide an update on the SEC process. -We might receive information that a U.S. listing is being prepared ahead of the commercial launch. An approximate timeline for the listing is provided. According to previous information, they could potentially come with two simultaneous offerings: ADS offering: American Depositary Shares representing ordinary shares. Parallel private placement: New ordinary shares sold to qualified investors in Europe. Shareholders who have sold recently might expect dilution from the aforementioned offerings. A listing in the U.S. before a potential approval could make it possible for Hansa to: Establish relationships with U.S. institutional investors. Increase visibility in the U.S. biotech market. Strengthen its financial position ahead of commercialization. Create interest among investors ahead of the FDA decision. If they proceed with the aforementioned offerings before PDUFA - it can also serve as an extra financial safety net if the FDA issues a CRL instead of an approval. This could give Hansa access to new capital before the binary regulatory event. An important detail is that the SEC normally requires the registration statement to be made public at least 15 days prior to a road show when the confidential review process is used. My interpretation is therefore that a capital raise before PDUFA could be rational even if management is optimistic about an approval. It can reduce the risk that the company is forced to raise money under pressure after a negative outcome. At the same time, a large new share issue before the decision could mean significant dilution for existing shareholders. My opinion and no advice. From Hansa 21 Aug 2026: "a potential initial public offering of American Depositary Shares ("ADSs"), representing the Company's ordinary shares, in the United States and a potential concurrent private placement of its ordinary shares in Europe to certain qualified investors (together, the "Global Offering")." From SEC - Enhanced Accommodations for Issuers Submitting Draft Registration Statements Consistent with our past practices, we will continue to review draft initial registration statements submitted under the Securities Act and Exchange Act Section 12(b), and their related revisions, on a nonpublic basis provided that the issuer confirms in a cover letter to the nonpublic draft submission that it will publicly file its registration statement and nonpublic draft submissions at least 15 days prior to any road show or, in the absence of a road show, at least 15 days prior to the requested effective date of the registration statement.
- ·1 päivä sittenOBV:s tekniska läge Kortsiktig struktur: Positiv Långsiktig trend: Fortfarande negativ Viktigaste motstånd:-6,82 M Viktigaste stöd: Stigande blå trendlinje De stigande bottnarna är positiva, men jag skulle vilja se ett utbrott genom motståndet innan jag betraktar OBV som tydligt bullish. OBV ser idag ut att avvisas vid det viktigaste motståndet och kan komma falla ner mot den stigande blå stödlinjen, kommer den under så försvagas den positiva bilden betydligt. Då riskerar vi att få en ny period av distribution. Min åsikt och inget råd.These analyses are not that interesting in this company, it's probably more FDA yes or no that one sits for
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 640 | ||
| 500 | ||
| 786 | ||
| 2 370 | ||
| 120 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 11.11. | ||
2026 Q2 - tulosraportti 22.7. | ||
2026 Q1 - tulosraportti 23.4. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 30.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 231 290 | 2 231 290 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 231 290 | 2 231 290 | 0 | 0 |
2026 Q3 - tulosraportti
UUTTA
Tänään
‧54 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 11.11. | ||
2026 Q2 - tulosraportti 22.7. | ||
2026 Q1 - tulosraportti 23.4. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 30.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sitten · MuokattuHansa upward trend since April - and on the way out of all resistance. 50 this week is not completely out of the question to imagine. Thinking we will probably check the top from 2/9 with close at 46.68 and intraday 48.22 Thu-Fri - or at the latest next week.
- ·10 t sittenCosts up by 34,3% - ouch Now burning 213 million per quarter. Zero revenue from products - as expected. License revenue - as expected. Zero new information regarding FDA and SEC (IPO)?? - are you paying attention at all? There won't be anything until December - that is indeed THE binary event we have been waiting for for a long time. So of course the report is completely and utterly as expected.
- ·1 päivä sitten"A bearish engulfing candle is a two-bar technical reversal pattern suggesting that an uptrend may be about to turn downward." https://dailypriceaction.com/blog/how-to-trade-the-bearish-engulfing-pattern/+13.3% :-) - not quite downwards in my chart !! One can almost assume with 100% certainty that when you "warn" that NOW NOW NOW your "analyses" have shown that it is in danger of falling - then it rises :-). Your investments must cost you monstrous sums - so I think you are very very rich, if you can afford to follow your own "analyses".
- ·1 päivä sittenWhat can happen tomorrow in connection with the report?I think it is entirely reasonable to monitor the quarterly report as a potential information point for both the FDA process and the U.S. listing. What might happen tomorrow in connection with the report? -Hansa will likely communicate that the FDA process is proceeding according to plan. -The company may provide an update on the SEC process. -We might receive information that a U.S. listing is being prepared ahead of the commercial launch. An approximate timeline for the listing is provided. According to previous information, they could potentially come with two simultaneous offerings: ADS offering: American Depositary Shares representing ordinary shares. Parallel private placement: New ordinary shares sold to qualified investors in Europe. Shareholders who have sold recently might expect dilution from the aforementioned offerings. A listing in the U.S. before a potential approval could make it possible for Hansa to: Establish relationships with U.S. institutional investors. Increase visibility in the U.S. biotech market. Strengthen its financial position ahead of commercialization. Create interest among investors ahead of the FDA decision. If they proceed with the aforementioned offerings before PDUFA - it can also serve as an extra financial safety net if the FDA issues a CRL instead of an approval. This could give Hansa access to new capital before the binary regulatory event. An important detail is that the SEC normally requires the registration statement to be made public at least 15 days prior to a road show when the confidential review process is used. My interpretation is therefore that a capital raise before PDUFA could be rational even if management is optimistic about an approval. It can reduce the risk that the company is forced to raise money under pressure after a negative outcome. At the same time, a large new share issue before the decision could mean significant dilution for existing shareholders. My opinion and no advice. From Hansa 21 Aug 2026: "a potential initial public offering of American Depositary Shares ("ADSs"), representing the Company's ordinary shares, in the United States and a potential concurrent private placement of its ordinary shares in Europe to certain qualified investors (together, the "Global Offering")." From SEC - Enhanced Accommodations for Issuers Submitting Draft Registration Statements Consistent with our past practices, we will continue to review draft initial registration statements submitted under the Securities Act and Exchange Act Section 12(b), and their related revisions, on a nonpublic basis provided that the issuer confirms in a cover letter to the nonpublic draft submission that it will publicly file its registration statement and nonpublic draft submissions at least 15 days prior to any road show or, in the absence of a road show, at least 15 days prior to the requested effective date of the registration statement.
- ·1 päivä sittenOBV:s tekniska läge Kortsiktig struktur: Positiv Långsiktig trend: Fortfarande negativ Viktigaste motstånd:-6,82 M Viktigaste stöd: Stigande blå trendlinje De stigande bottnarna är positiva, men jag skulle vilja se ett utbrott genom motståndet innan jag betraktar OBV som tydligt bullish. OBV ser idag ut att avvisas vid det viktigaste motståndet och kan komma falla ner mot den stigande blå stödlinjen, kommer den under så försvagas den positiva bilden betydligt. Då riskerar vi att få en ny period av distribution. Min åsikt och inget råd.These analyses are not that interesting in this company, it's probably more FDA yes or no that one sits for
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 640 | ||
| 500 | ||
| 786 | ||
| 2 370 | ||
| 120 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 231 290 | 2 231 290 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 231 290 | 2 231 290 | 0 | 0 |